WallStSmart

BioNexus Gene Lab Corp Common stock (BGLC)vsBHP Group Limited (BHP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BHP Group Limited generates 727021% more annual revenue ($53.99B vs $7.42M). BHP leads profitability with a 19.0% profit margin vs -40.2%. BHP earns a higher WallStSmart Score of 65/100 (C+).

BGLC

Avoid

29

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 6.7Quality: 8.0
Piotroski: 2/9Altman Z: 2.31

BHP

Buy

65

out of 100

Grade: C+

Growth: 5.3Profit: 8.5Value: 3.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BGLCUndervalued (+75.4%)

Margin of Safety

+75.4%

Fair Value

$7.92

Current Price

$2.09

$5.83 discount

UndervaluedFair: $7.92Overvalued
BHPSignificantly Overvalued (-84.5%)

Margin of Safety

-84.5%

Fair Value

$43.18

Current Price

$79.30

$36.12 premium

UndervaluedFair: $43.18Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BGLC2 strengths · Avg: 10.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

BHP5 strengths · Avg: 9.0/10
Market CapQuality
$201.45B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
40.7%10/10

Strong operational efficiency at 40.7%

Return on EquityProfitability
24.7%9/10

Every $100 of equity generates 25 in profit

EPS GrowthGrowth
27.5%8/10

Earnings expanding 27.5% YoY

Free Cash FlowQuality
$4.31B8/10

Generating 4.3B in free cash flow

Areas to Watch

BGLC4 concerns · Avg: 2.5/10
Market CapQuality
$5.37M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-35.2%2/10

ROE of -35.2% — below average capital efficiency

Revenue GrowthGrowth
-80.8%2/10

Revenue declined 80.8%

BHP1 concerns · Avg: 2.0/10
PEG RatioValuation
5.952/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : BGLC

The strongest argument for BGLC centers on Price/Book, Debt/Equity.

Bull Case : BHP

The strongest argument for BHP centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 19.0% and operating margin at 40.7%. Revenue growth of 10.8% demonstrates continued momentum.

Bear Case : BGLC

The primary concerns for BGLC are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : BHP

The primary concerns for BHP are PEG Ratio.

Key Dynamics to Monitor

BGLC profiles as a turnaround stock while BHP is a mature play — different risk/reward profiles.

BGLC carries more volatility with a beta of 2.31 — expect wider price swings.

BHP is growing revenue faster at 10.8% — sustainability is the question.

BHP generates stronger free cash flow (4.3B), providing more financial flexibility.

Bottom Line

BHP scores higher overall (65/100 vs 29/100), backed by strong 19.0% margins and 10.8% revenue growth. BGLC offers better value entry with a 75.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BioNexus Gene Lab Corp Common stock

BASIC MATERIALS · SPECIALTY CHEMICALS · USA

BioNexus Gene Lab Corp. The company is headquartered in Kuala Lumpur, Malaysia.

BHP Group Limited

BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA

BHP Group engages in the natural resources business in Australia, Europe, China, Japan, India, South Korea, the rest of Asia, North America, South America and internationally. The company is headquartered in Melbourne, Australia.

Want to dig deeper into these stocks?